Parkinson's Drug Permax Found to Increase Cardiac Valve Problems

Joe Saunders

Attorney
(866) 735-1102 Ext 340

0 CommentsPrint ArticleSubscribe

The journal Drug Injury Watch reports that "new study published in the March 2007 issue of the medical journal Archives of Neurology provides further support to the theory that the long-term use of Permax (pergolide) for Parkinson's disease increases the risk of valvulopathy, primarily cardiac valve regurgitation. In comparison, the same study found that Mirapex (pramipexole) and Requip (ropinirole), two non-ergot-derived dopamine agonists used for the treatment of Parkinson's disease, were not associated with this increased risk of heart valve damage."